By Tom Lehman 4:53pm, November 4, 2013The Attorney General's office says a major drug company is paying Delaware $2 million to resolve fraud allegations.
Johnson & Johnson is paying the funds as part of a $1.2 billion national settlement against the New Jersey based company and its subsidiary Janssen Pharmaceuticals.
The settlement is an effort to resolve allegations that the companies marketed and promoted antipsychotic drugs Risperdal and Invega for uses that weren't FDA approved or medically indicated.
The justice department also says the companies made false and misleading statements regarding the safety of the two drugs and paid illegal kickbacks to healthcare professionals and long-term care pharmacy providers to encourage or induce them to prescribe Risperdal to children, teens or the elderly.
This material may not be published, broadcast, rewritten, or redistributed.